Indications and Timing of Allogeneic Bone Marrow Transplantation in Myelodysplastic Syndromes

References

• Koeffler H. P. Myelodysplastic syndromes (Preleukemia). Semin. Haematol 1986; 23: 284–299
   PubMed Web of Science ®Google Scholar
• List A. F., Jacobs A. Biology and pathogenesis of the myelodysplastic syndromes. Semin. Oncol. 1992; 19: 14–24
   PubMed Web of Science ®Google Scholar
• Raza A., Gezer S., Mundle S., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268–276
   PubMed Web of Science ®Google Scholar
• Bennet J. M., Catovsky D., Daniel M. T., et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982; 51: 189–199
   PubMed Web of Science ®Google Scholar
• Tricot G., Boogaerts M. A., De Wolf‐Peeters C., et al. The myelodysplastic syndromes : different evolution patterns based on sequential morphological and cytogenetic investigations. Br. J. Haematol 1985; 59: 659–670
   PubMed Web of Science ®Google Scholar
• Jacobs A. Genetic lesions in preleukemia. Leukemia 1991; 5: 277–282
   PubMed Web of Science ®Google Scholar
• Coiffier B., Adeleine P., Viala J. J., et al. Dysmyelopoietic syndromes. A search for prognostic factors in 193 patients. Cancer 1983; 52: 83–90
   PubMed Web of Science ®Google Scholar
• Foucar K., Langdon R. M., Armitage J. O., et al. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer 1985; 56: 553–561
   PubMed Web of Science ®Google Scholar
• Kerkhofs M., Hermans J., Haak H. L., Lecksma C. H. W. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br. J. Haematol 1987; 65: 73–81
   PubMed Web of Science ®Google Scholar
• Levine E. G., Bloomfiel C. D. Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Semin. Oncol. 1992; 19: 47–84
   PubMed Web of Science ®Google Scholar
• Mufti G. J., Stevens J. R., Oscier D. G., et al. Myelodysplastic syndromes: a scoring system of prognostic significance. Br. J. Haematol 1985; 59: 425–433
   PubMed Web of Science ®Google Scholar
• Worsley A., Oscier D. G., Stevens J., et al. Prognostic features of chronic myelomonocytic leukemia: a modified Bournemouth score gives the best prediction of survival. Br. J. Haematol. 1988; 68: 17–21
   PubMed Web of Science ®Google Scholar
• Sanz G. F., Sanz M. A., Vallespi T., et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395–408
   PubMed Web of Science ®Google Scholar
• Aul C., Gattermann N., Heyll A., et al. Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6: 52–59
   PubMed Web of Science ®Google Scholar
• Tricot R., Vlietinck R., Boogaerts M. A., et al. Prognostic factors in the myelodysplastic syndromes: Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br. J. Haematol 1985; 60: 19–32
   PubMed Web of Science ®Google Scholar
• Morel P., Hebbar M., Lai J. L., et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report of 408 cases. Leukemia 1993; 7: 1315–1323
   PubMed Web of Science ®Google Scholar
• Aul C., Schneider W. The role of low‐dose cyto‐sine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 1989; 64: 1812–1818
   PubMed Web of Science ®Google Scholar
• Koeffler M. P., Heitjan D., Mertelsmann R., et al. Randomized study of 13‐Cis retinoic acid v placebo in the myelodysplastic disorders. Blood 1988; 71: 703–708
   PubMed Web of Science ®Google Scholar
• Aul C., Runde V., Gatterman N. All‐trans retinoic acid in patients with myelodysplastic syndromes: Results of a pilot study. Blood 1993; 82: 2967–2974
   PubMed Web of Science ®Google Scholar
• Holcombe R. F. Mini dose interferon α‐2a in the treatment of myelodysplasia. Leukemia 1993; 7: 192–195
   PubMed Web of Science ®Google Scholar
• Andreeff M., Stone R., Michaeli J., et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: A phase II clinical trial with a differentiation‐inducing agent. Blood 1992; 80: 2604–2609
   PubMed Web of Science ®Google Scholar
• Silverman L. R., Holland J. F., Weinberg R. S., et al. Effects of treatment with 5‐Asacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993; 7: 21–29
   PubMed Web of Science ®Google Scholar
• Gradishar W. J., Le Beau M. M., O'Laughlin R., et al. Clinical and cytogenetic responses to granulocyte‐macrophage colony‐stimulating factor in therapy‐related myelodysplasia. Blood 1992; 80: 2463–2470
   PubMed Web of Science ®Google Scholar
• Ganser A., Ottman O. G., Seipelt G., et al. Effect of long term treatment with recombinant human interleukin‐3 in patients with myelodysplastic syndromes. Leukemia 1993; 7: 696–701
   PubMed Web of Science ®Google Scholar
• Hellström‐Lindberg. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta‐analysis of 205 patients from 17 studies. Br. J. Haematol. 1995; 89: 67–71
   PubMed Web of Science ®Google Scholar
• Gordon M. S., Nemunaitis J., Hoffman R., et al. A phase 1 trial of recombinant human interleukin‐6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85: 3066–3076
   PubMed Web of Science ®Google Scholar
• Fenaux P., Morel P., Rose C., et al. Prognostic factors in adult De Novo myelodysplastic syndromes treated by intensive chemotherapy. Br. J. Haematol. 1991; 77: 497–501
   PubMed Web of Science ®Google Scholar
• Wattel E., Solary E., Caillot D., et al. Prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Blood 1996; 88(suppl 1)130, (abstract)
   PubMedGoogle Scholar
• Appelbaum F. R., Storb R., Ramberg R. E., et al. Treatment of preleukemia syndromes with marrow transplantation. Blood 1987; 69: 92–96
   PubMed Web of Science ®Google Scholar
• O'Donnell M. R., Nademanee A. P., Synder D. S., et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J. Clin. Oncol. 1987; 5: 1822–1826
   PubMed Web of Science ®Google Scholar
• Bélanger R., Gyger M., Perreault C., et al. Bone marrow transplantation for myelodysplastic syndromes. Br. J. Haematol. 1988; 69: 29–33
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Holler E., Bender‐Götze C., et al. Myeloablative conditioning for marrow transplantation in myelodysplastic syndromes and paroxysmal nocturnal haemo‐globinuria. Bone Marrow Transplant. 1989; 4: 29–34
   PubMed Web of Science ®Google Scholar
• Guinan E. C., Tarbell N. J., Tantravahi R., Weinstein H. J. Bone marrow transplantation for children with myelodysplastic syndromes. Blood 1989; 73: 619–622
   PubMed Web of Science ®Google Scholar
• Marmont A. M., Horowitz M. M. Outcome of allogeneic bone marrow transplantation for myelodysplastic syndromes. Bone Marrow Transplant. 1990; 5(suppl 2)71, (abstract)
   Google Scholar
• De Witte T., Zwaan F., Hermans J., et al. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the leukaemia working party of the European Bone Marrow Transplantation Group (EBMTG). Br. J Haematol 1990; 74: 151–155
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Barrall J., Storb R., et al. Bone marrow transplantation for patients with myelodysplasia. Ann. Intern. Med. 1990; 112: 590–597
   PubMed Web of Science ®Google Scholar
• Longmore G., Guinan E. C., Weinstein H. J., et al. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J. Clin. Oncol 1990; 8: 1707–1714
   PubMed Web of Science ®Google Scholar
• Sutton L., Leblond V., Le Maignan C., et al. Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia : outcome of 86 patients. Bone Marrow Transplant. 1991; 7(suppl 2)39
   PubMedGoogle Scholar
• Nevill T. J., Shepherd J. D., Reece D. E., et al. Treatment of myelodysplastic syndrome with busulfan‐cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant. 1992; 10: 445–450
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V., Karanes C., Uberti J., et al. Busulfan‐based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993; 81: 2194–2199
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Appelbaum F. R., Fisher L. D., et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677–681
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Appelbaum F. R., Storb R. An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk. Lymph. 1995; 17: 95–99
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Appelbaum F. R., Schoch G., et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of Busulfan, Cyclophosphamide, and total‐body irradiation and analysis of prognostic factors. J Clin. Oncol. 1996; 14: 220–226
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Appelbaum F. R., Schoch G., et al. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. Blood 1996; 87: 51–58
   PubMed Web of Science ®Google Scholar
• Nichols K., Parsons S. K., Guinan E. Long‐term follow‐up of 12 pediatric patients with primary myelodysplastic syndrome treated with HLA‐identical sibling donor bone marrow transplantation. Blood 1996; 87: 4020–4022
   PubMed Web of Science ®Google Scholar
• Sutton L., Chastang C., Ribaud P., et al. Factors influencing outcome in De Novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long‐term study of 71 patients. Blood 1996; 88: 358–365
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Anasetti C., Appelbaum F. R., et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemia. Br. J. Haematol 1996; 93: 59–67
   PubMed Web of Science ®Google Scholar
• Ballen K. K., Gillilaud D. G., Guinan E. C., et al. Bone marrow transplantation for therapy‐related myelodysplasia: comparison with primary myelodysplasia. Blood 1995; 86(suppl 1)95, (abstract)
   Google Scholar
• Fung H. C., Sheperd J. D., Nautel S. H., et al. Allogeneic bone marrow transplantation for adults with primary myelodysplastic syndrome: Evaluation of prognostic factors. Blood 1996; 88(suppl 1)480, (abstract)
   Google Scholar
• Runde V., De Witte T., Arnold R., et al. Bone marrow transplantation from HLA‐identical siblings as first line treatment in patients with myelodysplastic syndromes or secondary acute myelogenous leukemia: An european survey. Blood 1995; 86(suppl 1)96, (abstract)
   Google Scholar
• Geller R. B., Sarel R., Piantadosi S., et al. Allogeneic bone marrow transplantation after high dose busul‐fan and cyclophosphamide regimen. Blood 1989; 73: 2209
   PubMed Web of Science ®Google Scholar
• Tutschka P. J., Capelan E. A., Klein J. P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382
   PubMed Web of Science ®Google Scholar
• Keraan N. A., Bartsch G., Ash R. C., et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N. Engl. J. Med. 1993; 328: 593–602
   PubMed Web of Science ®Google Scholar
• Clift R. A., Buchner C. D., Appelbaum F. R., et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 1991; 77: 1660–1665
   PubMed Web of Science ®Google Scholar
• Lynch M. H. E., Petersen F. B., Appelbaum F. R., et al. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant. 1995; 15: 59–64
   PubMed Web of Science ®Google Scholar